论文部分内容阅读
目的:探讨药物致继发性血小板增多症(ST)的临床特点、机制及防治措施,为临床安全用药提供参考。方法:检索1996~2016年国内外发表的药物导致ST的文献,按年龄、性别、导致ST的药物种类和分布、药物致ST的处理与转归等进行统计分析。结果:共检索到198例药物致ST,涉及8个种类的30种不同药物,以抗肿瘤药、血液系统药物和抗菌药为主;198例患者中,男112例(56.6%),女86例(43.4%);有14例出现血栓,发生率为7.0%。结论:对于药物引起的ST,如未及时处理,可能导致血栓形成,应用此类药物时应定期监测血小板水平,保证用药安全。
Objective: To investigate the clinical features, mechanism and prevention and treatment of drug-induced secondary thrombocythemia (ST), and to provide reference for the clinical use of drug. Methods: The literatures about ST-induced drugs published at home and abroad from 1996 to 2016 were retrieved and analyzed by age and sex, the type and distribution of drugs leading to ST, the treatment and outcome of ST-induced drugs. Results: A total of 198 drugs were found in ST, involving 30 kinds of different drugs in 8 categories, with antineoplastic drugs, blood system drugs and antibacterial drugs as the main ones. Of the 198 patients, 112 (56.6%) were male and 86 Cases (43.4%); thrombosis occurred in 14 cases, the incidence was 7.0%. Conclusion: For drug-induced ST, if not treated in time, it may lead to thrombosis. The application of such drugs should be regularly monitored platelet levels, to ensure drug safety.